Ascelia Pharma AB (DE:7ZA)
FRANKFURT:7ZA
7ZA Stock Chart & Stats
€0.29
>-€0.01(-1.21%)
At close: 4:00 PM EST
€0.29
>-€0.01(-1.21%)
Day’s Range― - ―
52-Week Range€0.17 - €0.47
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€34.17M
Enterprise Value€336.69M
Total Cash (Recent Filing)€33.89M
Total Debt (Recent Filing)€689.00K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding133,535,460
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€8.11M
Bulls Say, Bears Say
Bulls Say
Very Low Financial LeverageExtremely low debt reduces short- to medium-term solvency risk and preserves strategic optionality while the company remains pre-revenue. That conservatism limits fixed financing costs, making it easier to pursue partnerships or raise equity without immediate debt servicing pressure, supporting runway resilience over months.
Lead Oncology Imaging Candidate Targets Unmet NeedOrviglance addresses a structural clinical niche—patients unsuitable for gadolinium—giving the company a differentiated product profile. A validated diagnostic alternative can create durable commercial and partnership opportunities, improve adoption potential in specialty imaging, and support licensing or commercialization deals if clinical/regulatory milestones are met.
Improving Loss And Burn Trend Versus Prior YearsA materially reduced cash burn and narrower losses versus earlier years indicate program progression and better cost control. That trend improves the company's medium-term funding profile and increases the likelihood management can reach clinical inflection points before requiring larger financings, supporting sustainability over the next several months.
Bears Say
No Revenue BaseBeing development-stage with no product revenue leaves the company fully reliant on external financing or partnerships to fund operations. Absence of commercial cash flow means financial sustainability hinges on successful trial outcomes or capital raises, increasing dilution and execution risk over the medium term.
Sizable Ongoing Cash BurnPersistent negative operating and free cash flow of this magnitude will deplete available resources without new funding. Continued high burn constrains strategic flexibility, forces reliance on capital markets or partners, and raises the risk of dilutive financings that can alter control or long-term upside for existing shareholders.
Eroding Equity And Negative ReturnsDeclining equity and assets alongside deeply negative ROE reflect capital consumption from ongoing losses. This erosion weakens the balance sheet cushion, reduces ability to absorb setbacks, and may complicate future financing terms or partnership negotiations, limiting the firm's durability if clinical or market progress slows.
Ascelia Pharma AB News
7ZA FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was €0.17 and its highest was €0.47 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is €34.17M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 63 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on May 12, 2026. The company reported -€0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.012.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -€0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in DE:7ZA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―